At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 31 enrolled
Drug / intervention
Buprenorphine +1 moredrug
Likely dose
Buprenorphine 0.2 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Incomplete Response in Late-Life Depression: Getting to Remission With Buprenorphine
In Brief
A Phase 2 clinical trial evaluating Buprenorphine and Placebo for Depression and Major Depressive Disorder. Completed, enrolled 31 participants across 1 site.
Detailed Summary
The purposes of this project are to examine the feasibility, safety, tolerability and clinical effect of low-dose buprenorphine as a novel treatment for late-life treatment-resistant depression and to develop preliminary data about mechanism of action.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepression, Major Depressive Disorder
CountriesUnited States
CollaboratorsNational Institute of Mental Health (NIMH)
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJun 2014
Enrollment StartAug 2014
Primary CompletionApr 2017
Study CompletionFeb 2018
TodayJul 2026
First PostedJun 27, 2014
Enrollment StartAug 1, 2014
Primary CompletionApr 1, 2017
Study CompletionFeb 1, 2018
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 12.0 years ago
Interventions
Buprenorphinedrug
low-dose buprenorphine (range 0.2 mg/day -- 2.0 mg/day)
Placebodrug
matched placebo